The Kampo medicines are more and more often used in recent years, usually together with the Western drugs. The need for the investigation of drug interactions between Kampo medicines and Western drugs are, therefore, widely recognized. In the present study, the effects of 3 Kampo medicines (Rikkunshito, Yokukansan and Boiogito) on the activity of cytochrome P450 (CYP), a superfamily of drug-metabolizing enzymes, were investigated in an in vitro study using human CYP recombinants. Their effects on the P-glycoprotein (P-gp), one of the major drug transporters, were also evaluated by the ATPase assay using human P-gp membranes and verapamil as a substrate. The inhibition rate of Rikkunshito, Yokukansan and Boiogito on human CYP3A4, 2C9, 2C19, 2D6 and 2E1 was less than 50% at the concentrations below 0.1 mg/ml except for the inhibition of CYP2D6 by Boiogito. Furthermore, none of the Kampo medicines affected the ATPase activity at the concentrations lower than 0.1 mg/ml, either in the absence or presence of verapamil, indicating their low inhibitory potency against P-gp. These findings indicate that Rikkunshito, Yokukansan and Boiogito are unlikely to cause clinically relevant drug interactions involving the inhibition of major CYP isozymes and P-gp.
Multi-drug combination therapy is now common for a number of diseases and the drug-drug interactions have attracted more and more attention in clinical practice. Among the various possible causes of drug-drug interactions, those related to pharmacokinetic processes such as drug metabolism and transport are regarded as the most frequent and clinically important.
Most of the interaction studies have focused on the interactions between Western drugs or those between food and Western drugs, and the possibility of Kampo medicines causing interactions with Western drugs has been ignored. Since Kampo medicines are being used more and more often in recent years, usually together with Western drugs, the need for the investigation of drug interactions between Kampo medicines and Western drugs is now widely recognized.
Several studies have investigated the effects of herbal medicines on the activity of cytochrome P450 (CYP), a major drug-metabolizing enzymes involved in biotransformation of xenobiotics, using human liver microsomes. [1] [2] [3] The effects of Kampo medicines on the metabolic enzymes and drug transporters, however, are not well established. 4) Three commonly-used Kampo medicines (Rikkunshito, Yokukansan and Boiogito) were selected in this study to investigate the possibility of their causing drug interactions. Rikkunshito improves the function of the alimentary system and is used for a number of conditions including gastritis and stomach atony. Yokukansan is used to treat psychoneurosis when patients complain of over-excitability, proneness to anger, irritability, or insomnia. Boiogito is a hydrostatic modulating drug used for conditions that include osteoarthritis of the knee and obesity. All these Kampo medicines are being used more and more widely in clinical practice, thus providing more chances that they will be administered together with other conventional medicines.
In the present study, in vitro studies were performed to investigate the effects of the above 3 Kampo medicines on the activity of CYP isozymes and P-glycoprotein (P-gp), one of the major drug transporters. P-gp, a member of the ATPbinding cassette (ABC) transporter family, is located in the cell membrane and transports drugs using the energy of ATP hydrolysis. P-gp is involved in the absorption, distribution and excretion of xenobiotics in various tissues.
3) The inhibition of CYP or P-gp by another drug could increase the plasma concentration of their substrates, leading to unwanted side effects or toxicity.
The inhibitory effects on CYP activity can be evaluated using recombinant enzymes and their fluorometric probe substrates. 5) In the present study, microsomes from insect cells expressing human CYP3A4, 2C9, 2C19, 2D6, and 2E1 were used to investigate the effects of Kampo medicines on the activity of these CYP isozymes. In addition, the effects on P-gp activity were evaluated in an ATPase assay using human P-gp membranes.
6) The possibility of Kampo medicines being inhibitors and substrates of P-gp was evaluated in the presence and absence of verapamil (a P-gp substrate), respectively. 
MATERIALS AND METHODS

Materials
Effects of Kampo Medicines on CYP and P-gp Activity in Vitro
Preparation of Kampo Test Solutions
Ten milliliters of distilled water was added to 200 mg dried extract of Rikkunshito, Yokukansan or Boiogito then the solutions were sonicated and vortexed followed by centrifugation at 1600ϫg, at room temperature for 15 min. The supernatants were used in the following experiments after dilution with distilled water.
CYP Inhibition Assay The inhibitory effects of Kampo medicines on CYP activities were determined using black 96-well microtiter plates (Nalge Nunc International, Roskilde, Denmark) and high throughput inhibitor screening kits for CYP3A4, 2C9, 2C19, 2D6, and 2E1 as described on the BD Gentest website (http://www.gentest.com). The experimental conditions for each CYP isozyme are summarized in Table 1 . Briefly, after 50 ml of Kampo test solutions (0.004, 0.04, 0.4, or 4 mg/ml) or positive control inhibitors (in Ͻ8% acetonitrile) were added to 50 ml of the cofactor solution (NADP ϩ , MgCl 2 , glucose-6-phosphate, glucose-6-phosphate dehydrogenase, control protein in potassium phosphate buffer, pH 7.4) and preincubated at 37°C for 10 min, the reaction was initiated by the addition of 100 ml prewarmed enzyme/substrate mixture. Reactions were terminated by addition of 75 ml of a stop solution (0.5 M Tris base : acetonitrileϭ1 : 4) at the various times given in Table 1 . Fluorescence in each well was measured using a microplate reader (GENios FL, Tecan Japan Co., Ltd, Tokyo, Japan) with the excitation and emission wavelengths shown in Table 1 .
The background fluorescence of the Kampo medicines was corrected by subtracting the values obtained by incubation without substrates. The IC 50 values were calculated by linear interpolation.
ATPase Assay The ATPase activity of human P-gp membranes was determined by measuring inorganic phosphate liberation according to the procedure reported by Sarkadi et al. 6) with some modifications. 7) The human P-gp membranes (2 mg of protein) were suspended in 10 ml incubation medium containing 50 mM Tris-Mes (pH 6.8), 2 mM DTT, 50 mM KCl, 2 mM EGTA, 2 mM ouabain, and 5 mM sodium azide. This medium was mixed in a BD Falcon 96-well plate (Becton Dickinson Labware, Franklin Lakes, NJ, U.S.A.) with 10 ml of Kampo test solution (0.005, 0.05, 0.5, or 5 mg/ml) or 1.5 mM orthovanadate, an inhibitor of the P-gp ATPase, and 10 ml of 250 mM verapamil or distilled water. The ATPase reaction was started by adding 20 ml of 4 mM MgATP solution to the reaction mixture and the incubation was maintained at 37°C for 30 min. The reaction was stopped by the addition of 20 ml of 5% trichloroacetic acid.
The liberated inorganic phosphate was measured by a method described by Carter and Karl. 8) Briefly, 42 ml of solution A (2 M HCl : 0.1 M sodium molybdateϭ4 : 3), 18 ml of solution B (0.042% (w/v) malachite green solution in 1% (w/v) polyvinyl alcohol), and 120 ml of solution C (7.8% (v/v) sulfuric acid) were added and the mixture was allowed to stand at room temperature for 1 h, after which the absorbance was measured at a wavelength of 630 nm using a microplate reader (Model 550, Bio-Rad, Hercules, CA, U.S.A.). The background phosphate levels in the Kampo test solutions were measured after incubation without MgATP and were found to be much lower than the amounts liberated in the ATPase reactions.
The amount of inorganic phosphate liberated in 30 min was estimated from the difference in phosphate levels between 0-min (reaction stopped immediately) and 30-min incubation periods and the vanadate-sensitive ATPase activity (nmol/mg protein/min) was obtained by subtracting the value in the presence of orthovanadate. The IC 50 values were calculated by linear interpolation.
RESULTS
Effects of Kampo Medicines on the CYP Activity
The effects of Rikkunshito, Yokukansan and Boiogito on the activities of CYP3A4, 2C9, 2C19, 2D6, and 2E1 are shown in Fig. 1 . For each CYP isozyme, the inhibitory effects of Kampo medicines were much smaller than the respective positive controls. The inhibition rate at the concentrations below 0.1 mg/ml was less than 50% except for the inhibition of CYP2D6 by Boiogito.
The IC 50 values for the CYP inhibition by Kampo medicines and positive controls are summarized in Tables 2 and 3 , respectively. While the IC 50 values for positive controls were lower than 1 mg/ml for all the CYP isozymes, those for Kampo medicines were higher than 0.1 mg/ml except for the inhibition of CYP2D6 by Boiogito (0.087 mg/ml).
Effects of Kampo Medicines on the ATPase Activity
The effects of Rikkunshito, Yokukansan and Boiogito on the ATPase activity are shown in Fig. 2 . In the absence of verapamil, the ATPase activity was unaffected by any of the Kampo medicines at concentrations below 0.1 mg/ml, while marked inhibition was observed at 1 mg/ml (Fig. 2A) . The results in the presence of 50 mM verapamil (Fig. 2B) showed a similar pattern as those in its absence.
The IC 50 values for the P-gp inhibition by Kampo medicines are summarized in Table 4 . The IC 50 values in the presence of verapamil tended to be higher than those in its absence, whereas there were no large differences in the values among the Kampo medicines. 894 Vol. 31, No. 5 
DISCUSSION
The effects of 3 Kampo medicines (Rikkunshito, Yokukansan and Boiogito) on the activities of major CYP isozymes and P-gp have been investigated in this study to evaluate the possibility that these Kampo medicines affect the pharmacokinetics of other drugs when administered concomitantly.
In the in vitro studies using recombinant CYP isozymes, Rikkunshito, Yokukansan and Boiogito produced only minor inhibition of human CYP3A4, 2C9, 2C19, 2D6, and 2E1 (Fig. 1, Table 2 ). The herbal compositions of the 3 Kampo medicines are summarized in Table 5 . Iwata et al. have investigated the inhibitory effects of various herbal medicines on CYP3A4 and CYP2D6 activity using human liver microsomes. 1) Their results indicate that none of the components of the 3 Kampo medicines used in the present study inhibits The IC 50 values were calculated by linear extrapolation using the data indicated in Fig. 1 . The IC 50 values were calculated by linear extrapolation using the data indicated in Fig. 1 . The IC 50 values were calculated by linear extrapolation using the data indicated in Fig. 2 . CYP3A4 with IC 50 values of less than 0.3 mg/ml. On the other hand, a relatively strong inhibition of CYP2D6 was observed by Sinomeni Caulis et Rhizoma (Boi) with an IC 50 value of 0.04 mg/ml. Among the 3 Kampo medicines used in the present study, only Boiogito contains Sinomeni Caulis et Rhizoma (Boi) (27% of total weight), which might be related to the relatively potent inhibitory effect of Boiogito on CYP2D6 (Fig. 1, Table 2 ).
The effects of Kampo medicines on P-gp were investigated in this study by an ATPase assay using human P-gp membranes. The ATPase activity in the absence of verapamil was not increased by any of the Kampo medicines studied ( Fig.  2A) , suggesting that none of the components of these Kampo medicines are transported by P-gp. Alternatively, the ATPase-stimulating effect of one of their components might be cancelled by the ATPase-inhibiting effect of another. Furthermore, none of the Kampo medicines affected the ATPase activity at concentrations less than 0.1 mg/ml, either in the absence or presence of verapamil (Fig. 2, Table 4 ), indicating their low inhibitory potency against P-gp. Among the herbal components of the 3 Kampo medicines used in the present study, Glycyrrhizae Radix (Kanzo) and Hoelen (Bukuryo) have been shown to inhibit P-gp activity in an in vitro study using human cervical carcinoma HeLa cells.
9) The content of Glycyrrhizae Radix (Kanzo) in Rikkunshito, Yokukansan and Boiogito is 4.7%, 7.3% and 8.1%, respectively, and that of Hoelen (Bukuryo) in Rikkunshito and Yokukansan is 18.6% and 19.5%, respectively (Table 5 ). It is possible that these herbal components may contribute to the P-gp inhibitory effects of the Kampo medicines at high concentrations.
In conclusion, Rikkunshito, Yokukansan and Boiogito produced little inhibition of human CYP3A4, 2C9, 2C19, 2D6, 2E1 and P-gp, indicating that these Kampo medicines are unlikely to cause clinically relevant drug interactions with the substrates of these enzymes/transporter. 
